Jifeng Feng - Researcher Profile | RDL Research Database

Publications

3 shown

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok , Yi‐Long Wu , Iveta Kudaba +97 more

2019 The Lancet 3175 citations

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng , Yoon‐Koo Kang , Zhendong Chen +18 more

Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and safe...

2008 The Lancet Oncology 5750 citations

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares , Mikhail Dvorkin , Yuanbin Chen +97 more

Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical acti...

2019 The Lancet 2014 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 10,939
Institution: Jiangsu Cancer Hospital

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-7979-2391

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.